[1]李 娟,曹平虎,唐先梅,等.双环醇片联合恩替卡韦治疗慢性乙型肝炎疗效及对患者肝功能的保护作用[J].陕西医学杂志,2021,50(10):1271-1274.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.024]
　LI Juan,CAO Pinghu,TANG Xianmei,et al.Curative effect of bicyclic alcohol tablets combined with entecavir in treatment of chronic hepatitis B and its protective effect on liver function[J].,2021,50(10):1271-1274.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.024]
点击复制

双环醇片联合恩替卡韦治疗慢性乙型肝炎疗效及对患者肝功能的保护作用
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
50
期数:
2021年10期
页码:
1271-1274
栏目:
药物与临床
出版日期:
2021-10-05

文章信息/Info

Title:
Curative effect of bicyclic alcohol tablets combined with entecavir in treatment of chronic hepatitis B and its protective effect on liver function
作者:
李 娟; 曹平虎; 唐先梅; 何 旭; 王 婷
(汉中市中心医院,陕西 汉中 723000)
Author(s):
LI Juan; CAO Pinghu; TANG Xianmei; HE Xu; WANG Ting
(Hanzhong Central Hospital,Hanzhong 723000,China)
关键词:
慢性乙肝;  双环醇片;  恩替卡韦;  肝功能;  肝纤维化;  免疫功能
Keywords:
Chronic hepatitis B;  Bicyclic alcohol tablets;  Entecavir;  Liver function;  Liver fibrosis;  Immune function
分类号:
R 575.1
DOI:
DOI:10.3969/j.issn.1000-7377.2021.10.024
文献标志码:
A
摘要:
目的:研究双环醇片联合恩替卡韦治疗慢性乙肝的疗效及对患者肝功能的保护作用。方法:选取136例慢性乙肝患者为研究对象,采用随机数字法分为对照组(n=68)和观察组(n=68),对照组给予恩替卡韦治疗,观察组在对照组基础上给予双环醇片治疗,比较两组临床疗效、乙肝表面抗原(HBsAg)、乙型肝炎e抗原(HBeAg)、HBV-DNA转阴率、肝功能指标[丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、总胆红素(TBIL)、白蛋白(ALB)]、肝纤维化指标[透明质酸酶(HA)、层粘连蛋白(LN)、Ⅲ型前胶原(PCⅢ)、Ⅳ型胶原(Ⅳ-C)]、免疫功能及不良反应发生率。结果:观察组治疗有效率高于对照组(91.18%与76.47%,P<0.05); 治疗后观察组HBV-DNA转阴率高于对照组(P<0.05); 治疗后两组ALB、CD3、CD4、CD4/CD8均升高,HBsAg、HBeAg、ALT、AST、TBIL、HA、LN、Ⅳ-C、PCⅢ、CD8均降低(P<0.05),且观察组ALB、CD3、CD4、CD4/CD8高于对照组,HBsAg、HBeAg、ALT、AST、TBIL、HA、LN、Ⅳ-C、PCⅢ、CD8低于对照组(均P<0.05); 两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:双环醇片联合恩替卡韦治疗慢性乙肝的疗效显著,可抑制HBsAg、HBeAg分泌,改善肝功能,延缓纤维化进展,提高免疫功能,且安全性较高。
Abstract:
Objective:To study the curative effect of bicyclic alcohol tablets combined with entecavir in the treatment of chronic hepatitis B and its protective effect on liver function.Methods:136 patients with chronic hepatitis B were selected and divided into control group(n=68)and observation group(n=68)by random number table method.The control group was treated with entecavir,and the observation group was treated with bicyclic alcohol tablets combined with entecavir.Clinical effects,negative conversion rates of hepatitis B surface antigen(HBsAg),hepatitis B e antigen(HBeAg)and HBV-DNA,liver function indicators[alanine aminotransferase(ALT),aspartate aminotransferase(AST),total bilirubin(TBIL),albumin(ALB)],liver fibrosis indicators[hyaluronidase(HA),laminin(LN),type Ⅲ procollagen(PCⅢ),type Ⅳ collagen(Ⅳ-C)],immune function,and the incidence of adverse reactions were compared between the two groups.Results:The effective rate of treatment in the observation group was higher than that in the control group(91.18% vs.76.47%,P<0.05).After treatment,the negative conversion rate of HBV-DNA in the observation group was higher than that in the control group(P<0.05).After treatment,ALB,CD3,CD4,and CD4/CD8 were increased,HBsAg,HBeAg,ALT,AST,TBIL,HA,LN,Ⅳ-C,PCⅢ,and CD8 were reduced in the two groups(all P<0.05).ALB,CD3,CD4,and CD4/CD8 in the observation group were higher than those in the control group,while HBsAg,HBeAg,ALT,AST,TBIL,HA,LN,Ⅳ-C,PCⅢ,and CD8 were lower than those in the control group(all P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Bicyclic alcohol tablets combined with entecavir is effective in the treatment of chronic hepatitis B.The combined treatment can inhibit the secretion of HBsAg and HBeAg,improve liver function,delay the progression of fibrosis,and improve immune function,with high safety.

参考文献/References:

[1] 蒋亚萍.富马酸替诺福韦酯与恩替卡韦治疗慢性乙型肝炎初治患者疗效与安全性比较[J].中国病原生物学杂志,2019,14(12):106-108.
[2] 樊橡伟,胡 勃,王向阳,等.肝苏胶囊联合水飞蓟宾胶囊治疗非酒精性脂肪肝及慢性乙型肝炎的疗效观察[J].陕西中医,2019,40(2):160-162,166.
[3] 李丽萍,闻 名,刘长明,等.恩替卡韦联合水飞蓟宾治疗慢性乙型肝炎患者疗效及其对肝功能、肝纤维化和炎性反应的影响[J].疑难病杂志,2019,18(3):247-250.
[4] 唐亦非,朱晓骏,黄凌鹰,等.和络舒肝胶囊联合双环醇治疗慢性乙型肝炎的临床研究[J].现代药物与临床,2018,33(3):573-577.
[5] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南[J].传染病信息,2005,11(z1):1-12.
[6] 魏 玉,李华河,张献波,等.恩替卡韦与阿德福韦酯治疗慢性乙型肝炎患者近期疗效和不良反应比较研究[J].实用肝脏病杂志,2018,21(3):137-138.
[7] 董远峰,彭 晶,陈艳炯,等.中性粒细胞淋巴细胞比值和血小板淋巴细胞比值在慢性乙肝患者外周血中的变化及其临床意义[J].陕西医学杂志,2020,49(9):1178-1181.
[8] 刘小莹,郑宏波,王山军,等.恩替卡韦单药方案维持对初始行拉米夫定+阿德福韦酯方案治疗慢性乙型肝炎及慢性乙型肝炎后肝硬化疗效影响[J].陕西医学杂志,2020,49(4):502-505.
[9] 孙 静,朱 琳,池 欣,等.恩替卡韦单药与联合干扰素抗病毒治疗对慢性乙型肝炎患者肝细胞癌发生风险的影响[J].临床肝胆病杂志,2020,36(9):65-69.
[10] 王芳芳,张国范,郭春霞,等.长期口服恩替卡韦治疗的慢性乙型肝炎患者换用α干扰素治疗临床疗效随访研究[J].实用肝脏病杂志,2018,21(5):721-724.
[11] 夏小芳,吴 建,施维群,等.扶正化瘀胶囊联合恩替卡韦治疗慢性乙型肝炎肝纤维化的疗效及对血液流变学和血清IL-17表达的影响[J].中国临床药学杂志,2020,29(5):20-24.
[12] 彭春仙,卢 滔,吴志宇,等.恩替卡韦或恩替卡韦联用阿德福韦酯治疗核苷(酸)类似物经治复发慢性乙型肝炎患者96周临床疗效[J].中华临床感染病杂志,2019,12(4):280-283.
[13] 王 颖,赵 奎,秦建忠.HBVcccDNA、HBsAg、HBVpgRNA联合检测对恩替卡韦治疗HBeAg阳性慢性乙型肝炎效果的预测价值[J].临床肝胆病杂志,2020,36(5):57-62.
[14] 孙 涛,杜凤梅.苦参素注射液联合双环醇对e抗原阳性慢性乙型肝炎患者血清T细胞亚群水平的影响[J].中国医师杂志,2019,21(4):586-589.
[15] 孙 菡,周新民,尹 芳,等.替比夫定治疗HBeAg阳性慢性乙型肝炎应答反应与HBeAg/HBsAg比值相关性研究[J].陕西医学杂志,2018,47(9):1137-1140.
[16] 沙尼亚?尼亚孜,柯比努尔?吐尔逊,潘珂君,等.长效干扰素α-2b联合阿德福韦酯或恩替卡韦治疗耐药HBeAg阳性乙型肝炎疗效及安全性比较[J].肝脏,2020,25(7):92-94,125.
[17] 庄海珍,林丽华.双环醇片联合恩替卡韦对慢性乙型肝炎患者血清乙型肝炎病毒表面抗原丙氨酸转氨酶水平的影响[J].中国药物与临床,2019,19(6):113-116.
[18] 王庆强,钱晶晶,左凌云,等.恩替卡韦治疗慢性乙型肝炎对机体炎症反应、肝功能及肝纤维化的影响[J].海南医学院学报,2018,24(14):22-25.
[19] 李 典,张 华,刘华仙,等.双环醇辅助替比夫定治疗妊娠中晚期慢性乙肝孕妇对其肝功能及婴儿结局的影响[J].解放军预防医学杂志,2019,37(9):146-147.
[20] 李 杰,刘红云,王小莉,等.聚乙二醇干扰素α-2b对慢性乙型肝炎患者的免疫调节及抗病毒效果分析[J].解放军医药杂志,2017,29(8):86-89.
[21] 高凌燕,陈 杰,王 江.软肝汤联合多烯磷脂酰胆碱与恩替卡韦治疗乙型肝炎并发肝硬化的疗效及对肝纤维化指标的影响[J].山西医药杂志,2020,49(6):49-51.
[22] 梁 超,毛重山,闫宏宪,等.重组人干扰素α-2b联合恩替卡韦对慢性乙型肝炎患者免疫功能的影响[J].药物评价研究,2019,42(5):967-969.
[23] 石 磊,朱瑞雪,安小翠,等.胸腺法新联合恩替卡韦治疗慢性病毒性乙型肝炎的疗效及对患者血清HA、Ⅳ-C、LN和免疫功能的影响[J].现代生物医学进展,2019,22(19):172-176.
[24] 钟文洲,李春芸.恩替卡韦对HBeAg阳性慢性乙型肝炎初治患者免疫功能的影响分析[J].河北医药,2019,41(6):119-121,126.

相似文献/References:

[1]王新伟,杨道坤△,梁海军,等.熊去氧胆酸对慢性乙型肝炎患者NAs抗病毒治疗后肝功能异常修复的临床研究*[J].陕西医学杂志,2020,49(1):112.

备注/Memo

备注/Memo:
基金项目:陕西省重点研发计划项目(2019SF-148)
更新日期/Last Update: 2021-10-08